Published in Vaccine Weekly, April 5th, 2000
Under the terms of the agreement, Corixa will contribute three targets initially and up to six targets a year during the six-year agreement. Abgenix will contribute its XenoMouse technology to the collaboration to generate, screen, and characterize human monoclonal antibodies directed against Corixa's antigens. Corixa, and in some cases Abgenix, will then be responsible for determining whether the characterized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly